Last reviewed · How we verify
ropivacaine (Naropin)
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local and regional anesthesia for surgery and acute pain management, Peripheral nerve blocks, Epidural anesthesia.
At a glance
| Generic name | ropivacaine (Naropin) |
|---|---|
| Also known as | Naropin |
| Sponsor | University of Zurich |
| Drug class | Local anesthetic (amide) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes, preventing depolarization and nerve impulse transmission. This results in local anesthesia in the area where it is administered. It is a long-acting amide local anesthetic with a lower cardiotoxicity profile compared to bupivacaine.
Approved indications
- Local and regional anesthesia for surgery and acute pain management
- Peripheral nerve blocks
- Epidural anesthesia
Common side effects
- Hypotension
- Bradycardia
- Nausea
- Headache
- Back pain
- Systemic toxicity (CNS and cardiac effects at high doses)
Key clinical trials
- External Oblique Intercostal Block Versus Transversus Abdominis Plane Combined With Rectus Sheath Block on Postoperative Pain in Laparoscopic Radical Gastrectomy (NA)
- OMT for Adhesive Capsulitis (PHASE4)
- A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia After Abdominal Surgery in China. (PHASE3)
- Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine (PHASE4)
- Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve (LFCN) Block or Wound Infiltration for Postoperative Analgesia in Anterior Approach Total Hip Arthroplasty: A Randomized Controlled Trial (NA)
- Does the Common Practice of Adding Diluted Epinephrine in Tranverse Abdominal Plan Block to Ropivacaine Significantly Decrease the Peak Systemic Resorption of Ropivacaine? (NA)
- Analgesic Effect of the QLB-3 for Patients Undergoing a Total Hip Surgery (NA)
- The Effects of Various Concentrations of Ropivacaine on the Onset and Duration of Ankle Blocks (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ropivacaine (Naropin) CI brief — competitive landscape report
- ropivacaine (Naropin) updates RSS · CI watch RSS
- University of Zurich portfolio CI